First-in-line 3D-printed intravaginal ring for nonhormonal contraception

Area of Science:

• Biomaterials Science
• Reproductive Health
• Drug Delivery Systems

Background:

• Unintended pregnancies necessitate effective and acceptable contraceptive methods globally.
• Existing long-acting contraceptives predominantly rely on exogenous hormones, with limited nonhormonal options like the copper intrauterine device (IUD).
• There is a need for innovative nonhormonal, long-acting contraceptive delivery systems to improve adherence and reliability.

Purpose of the Study:

• To develop and characterize a next-generation 3D-printed intravaginal ring (IVR) for the co-delivery of nonhormonal contraceptive agents.
• To demonstrate the flexibility of the 3D printing platform in achieving tunable release rates of lactic acid (LA) and glycerol monolaurate (GML).
• To investigate the drug loading and release mechanisms within the IVR matrix for sustained delivery over an extended period.

Main Methods:

• Fabrication of a 3D-printed IVR designed for the co-delivery of lactic acid (LA) and glycerol monolaurate (GML).
• In vitro characterization of the IVR to determine drug release kinetics by modifying ring properties and drug loading.
• Analysis of drug-drug interactions within the IVR matrix and elucidation of release mechanisms.

Main Results:

• The 3D-printed IVR platform demonstrated flexibility in achieving a range of lactic acid (LA) and glycerol monolaurate (GML) release rates.
• Sustained release of both LA and GML was achieved from the IVRs at target rates for durations exceeding 30 days.
• Insights were gained into the interactions of drugs with varying physiochemical properties within the IVR matrix, clarifying loading and release mechanisms.

Conclusions:

• A novel 3D-printed IVR platform enables the co-delivery of nonhormonal contraceptive agents, lactic acid (LA) and glycerol monolaurate (GML).
• The developed IVR technology offers tunable and sustained release profiles, demonstrating potential for long-acting, nonhormonal contraception.
• This platform represents a significant advancement in developing acceptable and effective contraceptive options, addressing a critical global health need.